SMMT250117P20000
- 2.40
- -0.30-11.11%
Summit Therapeutics Newsroom
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday?
Where Will Summit Therapeutics Be in 5 Years?
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.
Express News | Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY
Express News | Watching Summit Therapeutics; Traders Circulate Newsletter Mention
How Is The Market Feeling About Summit Therapeutics?
Summit Therapeutics Initiated at Overweight by Wells Fargo
Wells Fargo Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $30
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Jefferies Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31
Summit Therapeutics Initiated With a Buy at Jefferies
Summit Expands Workers' Compensation Coverage to Illinois
Is Summit Therapeutics (NASDAQ:SMMT) Using Debt In A Risky Way?
Express News | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trump Media Saw the Largest Increase in Short Interest in October
Summit Therapeutics (SMMT) Hurt Bronte Capital. Here's Why
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Express News | HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target
Strategic Position and Acquisition Interest Bolster Buy Rating for Summit Therapeutics